-

06:47:43 AM

XAIR Stock News

XAIR - Beyond Air Inc

10/19/20 7:00 AM

Nasdaq : XAIR

Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020

150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints All treatment groups had similar safety profiles and nitric oxide w as well tolerated with no drug-related serious adverse event s observed GARDEN

RHEA-AI

neutral

10/16/20 8:00 AM

Nasdaq : XAIR

clinical trial

Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

09/11/20 8:00 AM

Nasdaq : XAIR

conferences

Beyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

09/09/20 8:00 AM

Nasdaq : XAIR

conferences

Beyond Air® to Present Posters on CoronaVirus and Bronchiolitis at the CHEST 2020 Annual Meeting

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

08/27/20 8:00 AM

Nasdaq : XAIR

conferences

Beyond Air® to Present New Nitric Oxide Data in an e-Poster Presentation at the North America Conference on Lung Cancer 2020 (NACLC 2020)

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

08/10/20 4:01 PM

Nasdaq : XAIR

Beyond Air Publishes New Data on Nitric Oxide to Treat M. Abscessus in the Peer-Reviewed Journal Access Microbiology

Heterogeneity in M. abscessus susceptibility to

RHEA-AI

negative

08/06/20 7:45 AM

Nasdaq : XAIR

earnings

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business Update

U.S. COVID-19 study showing positive safety profile for patients enrolled to

RHEA-AI

neutral

07/23/20 8:00 AM

Nasdaq : XAIR

earnings

Beyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6th

Conference call at 8:30 a.m. ET Conference call at 8:30 a.m. ET

RHEA-AI

neutral

06/22/20 4:01 PM

Nasdaq : XAIR

earnings

Beyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020

Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints

RHEA-AI

neutral

06/08/20 5:29 PM

Nasdaq : XAIR

earnings

Beyond Air™ Scheduled to Announce Fiscal Year 2020 Financial Results on Monday, June 22nd

Conference call scheduled for Monday, June 22nd, at 4:30 p.m. Eastern Time Conference call scheduled for Monday, June 22nd, at 4:30 p.m. Eastern Time

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

XAIR Data

Websitewww.ait-pharm.com
CeoSteven Lisi
Security nameBeyond Air Inc
Issue typecs
Sic code3841
Tags
- Technology Services
- Packaged Software
- Manufacturing
- Other Industrial Machinery Manufacturing
Address825 E Gate Blvd Ste 320
StateNew York
CityGarden City
Zip11530-2135
CountryUS
Phone15166658200

About Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.